{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.61","upperLimit":"25.26","value":"10.9"},{"groupId":"OG001","lowerLimit":"5.03","upperLimit":"23.74","value":"14.80"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"Responders were AML participants who achieved CR, CRi, MLFS, PR or PRi based on investigator-reported best overall response and MDS participants who achieved CR, mCR, PR or SD based on investigator-reported best overall response. Whole blood mRNA analyses were performed on 21 mRNA candidates. Baseline mRNA level showing statistically significant correlation with clinical response are reported. Baseline mRNA levels statistically significant associated with best overall response was only seen for CCND2 (G1/S-Specific Cyclin D2).","dispersionType":"Full Range","groups":[{"description":"AML subjects who achieved CR, CRi, MLFS, PR, or PRi (AML investigator reported best overall response), and MDS subjects who achieved CR, mCR, PR, or SD (MDS investigator reported best overall response).","id":"OG000","title":"Phase 2 Fit (Biomarker, Responder)"},{"description":"AML subjects who did not achieve CR, CRi, MLFS, PR, or PRi; and MDS subjects who did not achieve CR, mCR, PR or SD were defined as non-responders for best overall response.","id":"OG001","title":"Phase 2 Fit (Biomarker, Non-Responder)"}],"paramType":"MEDIAN","populationDescription":"PD analysis set: all enrolled participants in the Phase 2 Fit portion who received at least 1 dose of glasdegib, and had at least 1 PD parameter from the corresponding assay sample with a baseline and an adequate post treatment assessment.","reportingStatus":"POSTED","timeFrame":"Baseline (Induction Cycle 1/Day -3 pre-dose)","title":"Baseline mRNA Levels Associated With Best Overall Response at Phase 2 Fit","type":"SECONDARY","unitOfMeasure":"Normalized expression units"}